The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | Differences in approaches to managing patients with multiple myeloma vs amyloidosis
Beth Faiman, PhD, MSN, APRN-BC, AOCN, BMTCN, FAAN, Cleveland Clinic, Cleveland, OH, comments on the differences in management between patients with multiple myeloma and patients with amyloidosis, explaining that patients with amyloidosis experience different toxicities to anti-myeloma therapies and may require dose adjustments. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
